Almitrine

Almitrine
Skeletal formula of almitrine
Ball-and-stick model of the almitrine molecule
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-N,N'-
    diprop-2-enyl-1,3,5-triazine-2,4-diamine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.044.054
Edit this at Wikidata
Chemical and physical data
FormulaC26H29F2N7
Molar mass477.564 g·mol−1
3D model (JSmol)
Melting point181 °C (358 °F)
SMILES
  • Fc1ccc(cc1)C(c2ccc(F)cc2)N4CCN(c3nc(nc(n3)NC\C=C)NC\C=C)CC4
InChI
  • InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33) checkY
  • Key:OBDOVFRMEYHSQB-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Almitrine (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC. It enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. A significant literature exists for this compound, including over 60 papers that Medline labels as reviews.

The clinical efficacy of almitrine-raubasine combination therapy for age related cerebral disorders and functional rehabilitation after stroke has been reviewed by Allain and Bentué-Ferrer.[1] They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in vascular cases. Their paper also suggests that other studies have shown a beneficial effect of this compound on neurosensory vascular disorders, specifically chorioretinal dysfunctions (visual symptomatology) and vertigo associated with electronystagmographic modifications. This paper further claims that the dosage and tolerance of the compound have been confirmed in a French multi-center study of 5,361 outpatients.

Synthesis

Almitrine synthesis: U.S. Patent 3,116,203 U.S. Patent 3,123,529 U.S. Patent 3,121,114

See also

References

  1. ↑ Allain H, Bentué-Ferrer D (1998). "Clinical efficacy of almitrine-raubasine. An overview". European Neurology. 39 Suppl 1 (Suppl. 1): 39–44. doi:10.1159/000052069. PMID 9516074.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.